Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

Talha Badar, MBBS, FCPS, Gloria Mattiuzzi, MD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Guillermo Garcia Manero, MD, Tapan M. Kadia, MD, Elias J. Jabbour, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 3887.

https://doi.org/10.1182/blood.V122.21.3887.3887

Published: 2013

Journal Articles

A Randomized, Double Blinded Study of Risedronate Versus Placebo for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia and Lymphoblastic Lymphoma

Kyle Cash, Robert Gagel, MD, J Lynn Palmer, PhD, Deborah A. Thomas, MD, Gloria Mattiuzzi, MD, Hagop M. Kantarjian, Susan O'Brien, MD, Mimi Hu, MD, Camilo Jimenez, MD, Maria E Cabanillas, MD

Blood (2011) 118 (21): 1486.

https://doi.org/10.1182/blood.V118.21.1486.1486

Published: 2011

Journal Articles

Clinical Significance of Cardiac Co-Morbidities and Risk Factors for Patients Treated with Imatinib.

Asifa Malik, MD, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Gloria Mattiuzzi, MD, Gloria Iliescu, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Tapan Kadia, MD, Susan O'Brien

Blood (2010) 116 (21): 4490.

https://doi.org/10.1182/blood.V116.21.4490.4490

Published: 2010

Journal Articles

Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure

Ali M Al-Ameri, MD, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Elizabeth Burton, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Xavier Badoux, MD, Susan O'Brien, Gloria Mattiuzzi, MD

Blood (2010) 116 (21): 1233.

https://doi.org/10.1182/blood.V116.21.1233.1233

Published: 2010

Journal Articles

Death In Complete Remission Among Patients with Acute Myeloid Leukemia: A Preventable Problem?

Gloria Mattiuzzi, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Stefan Faderl, MD, Tapan Kadia, MD, Zeev Estrov, MD, Gloria Iliescu, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD

Blood (2010) 116 (21): 2710.

https://doi.org/10.1182/blood.V116.21.2710.2710

Published: 2010

Journal Articles

Baseline Serum Ferritin Predicts Rate of Infection in Patients with Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.

Gloria Mattiuzzi, MD, Hesham M. Amin, MD, MSC, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD

Blood (2009) 114 (22): 1611.

https://doi.org/10.1182/blood.V114.22.1611.1611

Published: 2009

Journal Articles

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Deborah McCue, PhDP, B. Nebiyou Bekele, PhD, Lianchun Xiao, Gautam Borthakur, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 993.

https://doi.org/10.1182/blood.V114.22.993.993

Published: 2009

Journal Articles

Ten Years of Experience with Invasive Aspergillosis: Has Anything Changed?.

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Jennifer Ho, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 3687.

https://doi.org/10.1182/blood.V114.22.3687.3687

Published: 2009

Journal Articles

An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).

Gloria Mattiuzzi, MD, Amit Lahoti, Abdulla Salahudeen, Farhad Ravandi, M.D., Jorge Cortes, MD, Khanh Vu, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 1013.

https://doi.org/10.1182/blood.V114.22.1013.1013

Published: 2009

Journal Articles

Antifungal Prophylaxis (AFP) for Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Undergoing Intensive Chemotherapy: An Experience with 730 Pts.

Gloria Mattiuzzi, MD, Hagop Kantarjian, MD, Jennifer Ho, Guillermo Garcia-Manero, MD, Jorge Cortes, MD

Blood (2009) 114 (22): 3102.

https://doi.org/10.1182/blood.V114.22.3102.3102

Published: 2009

Journal Articles

Epoetin Alfa Reduces the Need for Red Blood Cell Transfusions and Does Not Affect Remission Rate or Survival When Given to Patients with Hematologic Malignancies Receiving Hyper-CVAD Therapy.

Gloria Mattiuzzi, MD, Hagop Kantarjian, Maria Cabanillas, Maria Foudray, Rebecca Garris, Susan O’Brien, Deborah A. Thomas, Jorge Cortes

Blood (2008) 112 (11): 903.

https://doi.org/10.1182/blood.V112.11.903.903

Published: 2008

Journal Articles

Acute Pulmonary Hemorrhage in Patients with Acute Myeloid Leukemia (AML) during Remission Induction Chemotherapy

Ali M Alameri, MD, Charles Asa Koller, Sherry Pierce, Gloria Mattiuzzi, MD

Blood (2008) 112 (11): 4031.

https://doi.org/10.1182/blood.V112.11.4031.4031

Published: 2008

Journal Articles

Outcome and Predictive Factors of Patients (pts) with Hematologic Malignancies (HM) Admitted to the Intensive Care Unit (ICU)

Gloria Mattiuzzi, MD, Jorge Cortes, Lianchun Xiao, Sherry Pierce, Hagop Kantarjian

Blood (2008) 112 (11): 3986.

https://doi.org/10.1182/blood.V112.11.3986.3986

Published: 2008

Journal Articles

Relaxing the Protected Environment Has Not Adversely Impacted Early Outcome of Older Patients (≥ 50 years) with AML and HR- MDS Receiving Induction Therapy

Gloria Mattiuzzi, MD, Edythe Greenberg, RN, Sherry Pierce, RN, Jorge Cortes, MD, Emil Freireich, MD, Susan O’Brien, MD, Hagop Kantarjian, MD

Blood (2008) 112 (11): 3988.

https://doi.org/10.1182/blood.V112.11.3988.3988

Published: 2008

Journal Articles

Long-Term Prognostic Impact of the Use of Erythropoiesis-Stimulating Agents (ESA) in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib.

Yesid Alvarado, MD, Hagop Kantarjian, MD, Dushyant Verma, MD, Gloria Mattiuzzi, MD, Ahmed Aribi, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 2959.

https://doi.org/10.1182/blood.V110.11.2959.2959

Published: 2007

Journal Articles

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Jennifer Cassat, Deborah Blamble, PHDP, B. Nebiyou Bekele, PhD, Miloslav Beran, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Jan Burger, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 2840.

https://doi.org/10.1182/blood.V110.11.2840.2840

Published: 2007

Journal Articles

Liposomal Amphotericin B IV (LIPO AB) Once Per Week Is Effective in the Prevention of Invasive Fungal Infections (IFI) in Patients (Pts) with Acute Leukemia: Preliminary Analysis of a Randomized Trial.

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Deborah Blamble, PHDP, Elihu Estey, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 1824.

https://doi.org/10.1182/blood.V110.11.1824.1824

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

A Randomized, Double Blinded Study of Risedronate Versus Placebo for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia and Lymphoblastic Lymphoma

Clinical Significance of Cardiac Co-Morbidities and Risk Factors for Patients Treated with Imatinib.

Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure

Death In Complete Remission Among Patients with Acute Myeloid Leukemia: A Preventable Problem?

Baseline Serum Ferritin Predicts Rate of Infection in Patients with Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.

Palonosetron (PALO) Given Daily for up to 5 Days Is Significantly Better Than Ondansetron (ONDA) in the Prevention of Delayed CINV in Patients (pts) with Acute Myelogenous Leukemia (AML).

Ten Years of Experience with Invasive Aspergillosis: Has Anything Changed?.

An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).

Antifungal Prophylaxis (AFP) for Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Undergoing Intensive Chemotherapy: An Experience with 730 Pts.

Epoetin Alfa Reduces the Need for Red Blood Cell Transfusions and Does Not Affect Remission Rate or Survival When Given to Patients with Hematologic Malignancies Receiving Hyper-CVAD Therapy.

Acute Pulmonary Hemorrhage in Patients with Acute Myeloid Leukemia (AML) during Remission Induction Chemotherapy

Outcome and Predictive Factors of Patients (pts) with Hematologic Malignancies (HM) Admitted to the Intensive Care Unit (ICU)

Relaxing the Protected Environment Has Not Adversely Impacted Early Outcome of Older Patients (≥ 50 years) with AML and HR- MDS Receiving Induction Therapy

Long-Term Prognostic Impact of the Use of Erythropoiesis-Stimulating Agents (ESA) in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib.

An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC).

Liposomal Amphotericin B IV (LIPO AB) Once Per Week Is Effective in the Prevention of Invasive Fungal Infections (IFI) in Patients (Pts) with Acute Leukemia: Preliminary Analysis of a Randomized Trial.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only